The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Safety and efficacy of teclistamab in patients with RRMM exposed to anti-BCMA: MajesTEC-1 Cohort C
|
Teclistamab, a B-cell maturation antigen (BCMA)-directed bispecific antibody therapy, was investigated and granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (RRMM) as a result of the pivotal MajesTEC-1 (NCT04557098) trial. Results from Cohort C of MajesTEC-1 trial on safety and efficacy of teclistamab in patients with prior exposure to anti-BCMA therapies were published in Blood by Touzeau, et al.1 |
| Key learnings: |
|
An overall response rate (ORR) of 52.5% was observed, with 47.5% of patients experiencing a very good partial response or better (≥VGPR) and 30% a complete response or better (≥CR).
|
|
The median progression-free survival and overall survival were 4.5 months and 15.5 months, respectively. |
|
The most common any grade treatment-emergent adverse events (TEAEs) included neutropenia, infections, and cytokine release syndrome.
|
|
The safety profile of teclistamab was largely comparable in patients with and without prior exposure to anti-BCMA therapy. |
|
The findings from the study demonstrate the clinical benefit of teclistamab as a therapeutic option for patients with RRMM previously treated with BCMA-targeted therapies. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
